Point72 Hong Kong LTD Aerie Pharmaceuticals Inc Transaction History

Point72 Hong Kong LTD

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 16, 2021	SELL	$15.16 - $18.97 $14,371 - $17,983	-948 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$13.12 - $20.9 $590 - $940	45 Added 4.98%	948 $17,000
Q4 2020 Feb 16, 2021	SELL	$9.12 - $14.49 $8,499 - $13,504	-932 Reduced 50.79%	903 $12,000
Q3 2020 Nov 16, 2020	SELL	$10.46 - $14.46 $16,704 - $23,092	-1,597 Reduced 46.53%	1,835 $22,000
Q2 2020 Aug 14, 2020	BUY	$12.0 - $16.13 $41,184 - $55,358	3,432 New	3,432 $51,000

Q1 2020 May 15, 2020	SELL	$11.84 - $25.52 $3,078 - $6,635	-260 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$17.72 - $25.1 $4,607 - $6,526	260 New	260 $6,000
Q3 2019 Nov 14, 2019	SELL	$18.41 - $28.0 $552 - $840	-30 Closed	0 $0
Q2 2019 Aug 14, 2019	BUY	$28.97 - $48.21 $869 - $1,446	30 New	30 $1,000
Q3 2018 Nov 14, 2018	SELL	$56.15 - $73.9 $954 - $1,256	-17 Closed	0 $0
Q2 2018 Aug 14, 2018	BUY	$47.85 - $70.45 $813 - $1,197	17 New	17 $1,000
Q4 2017 Feb 14, 2018	SELL	$50.85 - $65.1 $11,695 - $14,972	-230 Closed	0 $0
Q3 2017 Nov 14, 2017	BUY	$48.6 - $60.1 $11,178 - $13,823	230	230 $11,000

2.4M

Ticker AERI
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 49,390,500
Description
Aerie Pharmaceuticals, Inc., a pharmaceutical company, focuses on the discovery, development, and commercialization of ophthalmic therapies for open-angle glaucoma, dry eye, diabetic macular edema, and wet age-related macular degeneration in the United States. Its products include Rhopressa, a once-daily eye drop to reduce elevated intraocular p...

Get notified when there are updates to the investment portfolio of Point72 Hong Kong LTD, based on Form 13F filings with the SEC.

Stay updated on Point72 Hong Kong LTD with notifications on news.